MANNKIND CORP Deferred Federal Income Tax Expense (Benefit)
MANNKIND CORP (MNKD) reported Deferred Federal Income Tax Expense (Benefit) of -$12.58 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-26
- MANNKIND CORP deferred federal income tax expense (benefit) for fiscal 2025 was -$12.58M, a 182.23% decline from fiscal 2024.
- MANNKIND CORP deferred federal income tax expense (benefit) for fiscal 2024 was $15.30M.
- MANNKIND CORP deferred federal income tax expense (benefit) for fiscal 2023 was -$190.00K.
- MANNKIND CORP deferred federal income tax expense (benefit) for fiscal 2022 was -$5.61M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$12.58M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $15.30M 10-K · filed 2026-02-26 | |
| 2023-12-31 | -$190.00K 10-K · filed 2026-02-26 | $190.00K 10-K · filed 2024-02-27 |
| 2022-12-31 | -$5.61M 10-K · filed 2025-02-26 | |
| 2021-12-31 | -$5.17M 10-K · filed 2024-02-27 | |
| 2020-12-31 | -$4.38M 10-K · filed 2023-02-23 | |
| 2019-12-31 | -$8.55M 10-K · filed 2021-02-25 | |
| 2018-12-31 | -$9.16M 10-K · filed 2020-02-25 | |
| 2017-12-31 | $244.80M 10-K · filed 2019-02-26 | |
| 2016-12-31 | -$43.81M 10-K · filed 2019-02-26 | |
| 2015-12-31 | $109.51M 10-K · filed 2018-02-27 | |
| 2014-12-31 | $57.87M 10-K · filed 2017-03-16 | |
| 2013-12-31 | $59.38M 10-K · filed 2016-03-15 | |
| 2012-12-31 | $51.54M 10-K · filed 2015-03-02 | |
| 2011-12-31 | $48.64M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |